Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?

Eur Heart J. 2016 Nov 14;37(43):3260-3266. doi: 10.1093/eurheartj/ehw146. Epub 2016 Apr 20.


Recent discoveries have revealed that microRNAs (miRNAs) play a key role in the regulation of gene expression. In this review, we summarize the rapidly evolving knowledge about liver miRNAs (including miR-33, -33*, miR-223, -30c, -144, -148a, -24, -29, and -122) and their link to hepatic lipid metabolism, atherosclerosis and cardiovascular disease, non-alcoholic fatty liver disease, metabolic syndrome, and type-2 diabetes. With regards to its biomarker potential, the main focus is on miR-122 as the most abundant liver miRNA with exquisite tissue specificity. MiR-122 has been proposed to play a central role in the maintenance of lipid and glucose homeostasis and is consistently detectable in serum and plasma. This miRNA may therefore constitute a novel biomarker for cardiovascular and metabolic diseases.

Keywords: Biomarkers; Cardiovascular disease; Lipid metabolism; MicroRNAs.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Cardiovascular Diseases
  • Humans
  • Liver*
  • Metabolic Syndrome
  • MicroRNAs


  • Biomarkers
  • MicroRNAs